Calcineurin (Cn) is a calcium-activated serine/threonine protein phosphatase that is broadly 22 implicated in diverse cellular processes, including the regulation of gene expression. During 23 skeletal muscle differentiation, Cn activates the NFAT transcription factor but also promotes 24 differentiation by counteracting the negative influences of protein kinase C beta ( 
INTRODUCTION 36
Myoblast differentiation is an essential process during skeletal muscle development where 37 mononuclear myoblasts withdraw from the cell cycle and undergo fusion and other morphological 38 changes to form multi-nucleated myotubes. This process is coordinated by the family of myogenic 39 regulatory factors (MRFs) that include MyoD, myogenin, Myf5, and Mrf4 in cooperation with the 40 MEF family of transcription factors and other auxiliary transcriptional regulators. MRFs regulate 41 the commitment, determination, and differentiation of skeletal muscle progenitor cells. The ability 42 of MRFs to drive the myogenic gene expression needed for differentiate requires remodeling of 43 chromatin at target genes that depends on the recruitment of histone modifying and chromatin 44 remodeling complexes that alter nucleosome structure and the local chromatin environment (1-3). 45
The SWI/SNF (SWItch/Sucrose Non-Fermentable) complexes are large, multiprotein, 46 ATP-dependent chromatin remodeling enzymes (4-6) that alter nucleosome structure to promote 47 transcription, replication, recombination and repair (7-10). The chromatin remodeling activity of 48 the SWI/SNF enzyme is required for the initiation of many developmental and differentiation 49 programs (11) (12) (13) (14) including activation of myogenic genes upon differentiation signaling (15, 16) . 50
Mammalian SWI/SNF complexes contain one of two related ATPase subunits, either Brahma 51 related gene 1 (Brg1) or the ATPase Brahma (Brm), and a collection of at least 9 to 12 associated 52 protein known as Brg1/Brm -associated factors (Bafs) (4, 17, 18) . Mammalian SWI/SNF enzyme 53 function can be influenced by the assembly of different combination of Baf subunits around the 54 different ATPases (12, 19) . Furthermore, signal transduction pathways promote specific 55 posttranslational modifications of SWI/SNF subunit proteins that influence enzyme activity (15, 56 20-23) . In skeletal muscle differentiation, the p38 mitogen-activated protein kinase (MAPK) 57 phosphorylates the Baf60c subunit, which then allows the recruitment of the rest of SWI/SNF 58 were deposited at the Gene Expression Omnibus (GEO) database under accession number 126 GSE125914. The reviewer access token is krexscswllodxwn. 127
128
Chromatin immunoprecipitation (ChIP) assay. Chromatin immunoprecipitation assays were 129 performed as previously described (20, 48) with some modifications. Briefly, cells (4 ´ 10 6 ) were 130 cross-linked with 1% formaldehyde (Ted Pella Inc., Redding, CA) for 10 minutes at room 131 temperature. After quenching the formaldehyde with 125 mM glycine for 5 minutes, fixed cells 132 were washed twice with PBS supplemented with protease inhibitor cocktail and lysed with 1 ml 133 buffer A (10 mM Tris HCl, pH 7.5, 10 mM NaCl, 0.5% NP40, 0.5 µM DTT and protease 134 inhibitors) by incubation on ice for 10 minutes. The nuclei were pelleted, washed with 1 ml of 135 buffer B (20 mM Tris HCl, pH 8.1, 15 mM NaCl, 60 mM KCl, 1 mM CaCl2, 0.5 µM DTT) and 136 incubated for 30 minutes at 37°C in the presence of 1000 gel units of MNase (#M0247S, NEB, 137
Ipswich, MA) in 300 µl volume of buffer B. The reaction was stopped by adding 15 µl of 0.5 M 138 EDTA. Nuclei were pelleted and resuspended in 300 µl of ChIP buffer (100 mM Tris HCl, pH 8.1, 139 20 mM EDTA, 200 mM NaCl, 0.2 % sodium deoxycholate, 2% Triton X 100 and protease 140 inhibitors), sonicated for 10 minutes (30 sec-on/ 30 sec-off) in a Bioruptor 141 Denville, NJ) and centrifuged at 15,000 rpm for 5 minutes. The fragmented chromatin was between 142 200-500 bp as analyzed on agarose gels. Chromatin concentration was measured using Qubit 3 143 (Invitrogen). After preclearing with protein A agarose, chromatin (2-4 µg) was subjected to 144 immunoprecipitation with specific antibodies listed above, or with anti-IgG as negative control at 145 4°C overnight, and immunocomplexes were recovered by incubation with protein A agarose 146 magnetic beads (Invitrogen). Sequential washes of 5 minutes each were performed with buffers 147 A-D (Buffer A: 50 mM Tris pH 8.1, 10 mM EDTA, 100 mM NaCl, 1% Triton X 100, 0.1% sodium 148 deoxycholate; Buffer B: 50 mM Tris pH 8.1, 2 mM EDTA, 500 NaCl, 1% Triton-X100, 0.1% 149 sodium deoxycholate; Buffer C: 10 mM Tris pH 8.1, 1 mM EDTA, 0.25 M LiCl2; 1% NP-40, 1% 150 sodium deoxycholate; Buffer D: 10 mM Tris pH 8.1, 1 mM EDTA), immune complexes were 151 eluted in 100 µl of elution buffer (0.1 M NaHCO3, 1% SDS) for 30 minutes at 65°C, incubated 152 with 1 µl of RNnase A (0.5 mg/ml) for 30 minutes at 37°C, and reverse cross-linked by adding 6 153 µl of 5M NaCl and 1 µl of proteinase K (1 mg/ml) overnight at 65°C. DNA was purified using the 154 ChIP DNA clean & concentrator kit (Zymo Research, Irvine, CA). Bound DNA fragments were 155 analyzed by quantitative PCR using the SYBR Green Master Mix. Quantification was performed 156 using the fold enrichment method (2 -(Ct sample -Ct IgG) ) and shown as relative to a control region, the 157 promoter for the Pdx1 gene. Primer sequences are listed in Supplemental Table S1 . Primer 158 positions for each promoter are shown schematically in Supplemental Figure S1 . 159
Immunoprecipitation. 100 mm dishes of 24h differentiated C2C12 cells treated with FK506 or 160 with DMSO or 100 mm dishes of primary myoblasts expressing wildtype or Brg1 mutants were 161 washed with ice-cold PBS twice and lysed in 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 162 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1mM CaCl2 and supplemented with 163 complete protease inhibitors). Lysates were cleared by centrifugation and precleared with 164 PureProteome Protein A magnetic beads (Millipore) for 2 hours at 4°C. Next, cell extract was 165 incubated with 10 μl of Pan-Calcineurin A antibody (Cell Signaling Technologies) or 10 μl of 166
Brg1 antisera overnight at 4°C, followed by incubation with 100 µl with PureProteome Protein A 167 mix magnetic beads. After extensive washing of beads with washing buffer (24 mM Tris-HCl, pH 168 7.5, 300 NaCl, 0.5% NP-40 and 1mM CaCl2), precipitated proteins were eluted in Laemmli buffer 169 and detected by western blot analysis using chemiluminescent detection. expressed. More genes were up-regulated (373) than were downregulated (275) (Fig. 1A, B) Fig. 1C and Supplementary Fig. S2 ). Specific 195 myogenic genes were identified and labeled on the volcano plots in Fig. 1A . In contrast, we 196 observed up-regulation of genes associated with ossification, response to interferon and viruses, 197 and cardiovascular and blood vessel development. These results are potentially consistent with 198 documented roles for Cn in the regulation of NFAT function in these processes (52-54). We 199 performed de novo motif analysis on the differentially expressed genes. The most significantly 200 enriched motifs at the 24h post-differentiation were for Mef2 transcription factors and E-boxes 201 bound by the MRFs Myf5, myogenin and MyoD (Fig. 1D) We continued our analysis by identifying the groups of genes that showed treatment-specific changes 214 in gene expression over time. In total, 308 genes were identified. We analyzed the expression patterns 215 of these differentially expressed genes using Cluster Profiler (47). Genes differentially expressed 216 over time were clustered into 4 major groups, graphically presented by heat map ( Fig. 2A) and 217 expression kinetics (Fig. 2B) . We performed GO analysis for the differentially expressed genes in 218 these 4 clusters to gain additional insight into the biological processes regulated by calcineurin during 219 myoblast differentiation (Fig. 2C) . Cluster 1 included 95 genes that were down-regulated during 220 differentiation but were unchanged in the presence of the Cn inhibitor. GO terms significantly 221 enriched for this group of differentially expressed genes related to cell migration, motility and 222 adhesion. In addition, Cluster 1 included Inhibitor of differentiation (Id) proteins 1, 2 and 3 223 (Supplementary Table S3 Supplementary Table S3 . These data suggests that calcineurin regulates 236 multiple and diverse groups of genes during myoblast differentiation. 237
For further analysis, we focused on genes that were down-regulated in the presence of 238 FK506 and are important for muscle structure and/or function (Fig. 1A) . We first measured mRNA 239 expression level of several such genes to validate RNA-seq results; Myog, Ckm, Myh4, Mymk, 240 Tnnt3, Acta1 and Cav3 were analyzed by RT-qPCR. As expected, each of these genes were 241 increased over the course of the differentiation time course and each was significantly down-242 regulated by exposure to the Cn inhibitor, FK506 (Fig. 3) . These results confirmed that inhibition 243 of Cn during myoblast differentiation impairs expression of multiple myogenic genes that are 244 normally activated during differentiation. 245
246

Inhibition of calcineurin function prevents its binding to myogenic promoters 247
We previously showed that Cn associates with Brg1 and binds to the myogenin promoter early 248 after the start of the differentiation process (20). We hypothesized that the same model might be 249 true for other myogenic genes. Alternatively, Cn may directly regulate the myogenin promoter but 250 indirectly regulate other downstream genes and via the dependency of other genes on myogenin 251 for completing the differentiation process (57, 58). We performed chromatin immunoprecipitation 252 assays on the same panel of myogenic genes examined in Fig. 3 . PCR primers for ChIP were 253 designed to amplify the E-box containing regions within 1.5 Kb upstream of the TSS 254 (Supplementary Figure S1) . Cn did not interact with myogenic genes regulatory sequences in 255 proliferating myoblasts (GM), was weakly bound in undifferentiated cells at the start of 256 differentiation (0h DM), and was bound at all myogenic gene promoters in differentiated (48h 257 DM) cells (Fig. 4) . We conclude that Cn binding to myogenic promoters is a general occurrence 258 and FK506-mediated inhibition of Cn function impairs its ability to interact with target gene 259 promoters. The results suggest that Cn is a direct regulator of many, if not all, myogenic genes. 260 261
Cn inhibition blocks the interaction of the ATPase Brg1 and other subunits of the 262 mammalian SWI/SNF complex with myogenic promoters 263
We also performed ChIP assays to determine whether Brg1 recruitment to myogenic regulatory 264 sequences was dependent on calcineurin. We observed recruitment of Brg1 to regulatory 265 sequences in differentiated (48h DM) cells at all the tested myogenic genes. In cells treated with 266 FK506, Brg1 binding was significantly diminished at all promoters (Fig. 5A) . A subset of the 267 myogenic promoters was tested for the binding of Baf170, and Baf250A/Arid1A, which are other 268 subunits of the mammalian SWI/SNF enzyme complex. The results show that binding of these 269 other subunits paralleled Brg1 binding in that Cn inhibition blocked interaction of these proteins 270 to the promoters (Fig. 5B) . These findings indicate that Cn activity is necessary for the interaction 271 of mammalian SWI/SNF chromatin remodeling complexes with regulatory sequences of myogenic 272 genes. 273
274
Mutation of Brg1 sites of Cn activity prevents its interaction with myogenic gene promoters 275
In previous work, we showed that PKCb-mediated phosphorylation of Brg1 prior to the onset of 276 differentiation was counteracted by Cn-mediated dephosphorylation of Brg1 immediately after the 277 onset of differentiation (20). Serine amino acids targeted by PKCb/Cn mapped to 5' and 3' of the 278 Brg1 bromodomain. Mutation of these sites to the phosphomimetic amino acid glutamate (SE) 279 prevented myogenesis, whereas mutation to the non-phosphorylatable amino acid alanine (SA) 280 had no effect on differentiation (20). These experiments used primary myoblasts derived from 281 Brg1-deficient mice that were reconstituted with wildtype (WT)-, SA-, or SE-Brg1. We performed 282
ChIP experiments in differentiating cells and showed that Cn and Brg1 are bound to myogenic 283 promoters in myoblasts expressing WT-Brg1 (Fig. 6A, B) . The SE-Brg1 mutant was incapable of 284 binding; the repressive phosphorylation of Brg1 caused by PKCb is mimicked by the glutamate 285 substitutions, rendering Cn incapable of activating Brg1. As expected, the SA-Brg1 mutant, which 286 cannot be phosphorylated at the relevant PKCb target amino acids, bound Brg1 and Cn to 287 myogenic regulatory sequences (Fig. 6A, B) . These results are consistent with those obtained with 288 the Cn inhibitor, and they reinforce the conclusion that Cn function regulates Brg1 binding to 289 chromatin at myogenic gene regulatory sequences. 290 291
Cn inhibition does not impact the ability of Cn and Brg1 to interact 292
We previously showed that Cn and Brg1 can be co-immunoprecipitated from cell lysate of 293 differentiating cells (20) . Inhibition of Cn function with FK506 had no impact on the ability of 294 these proteins to be isolated in complex with each other (Fig. 7A) . As a complement to this 295 experiment, we looked at the interaction of Cn with Brg1 in differentiating myoblasts expressing 296 WT-, SA-, or SE-Brg1. Cn could interact with WT-, SA-, and SE-Brg1 mutants (Fig. 7B) , despite 297 the observation that SE-Brg1 was not competent for interaction with chromatin. These results 298
indicate that inhibition of Cn function and mutation of the sites of Cn activity on Brg1 do not affect 299 the interaction that exists between these regulatory proteins. The continued existence of Brg1 300 protein in the presence of the Cn inhibitor and when Cn-targeted residues are mutated to alanine 301 or glutamine suggests that the lack of appropriate phosphorylation or dephosphorylation does not 302 have significant impact on the steady-state levels of Brg1 and therefore is unlikely to be a major 303 regulator of protein stability. 304 305
Inhibition of calcineurin blocks MyoD binding to regulatory sequences of myogenic genes 306
Recruitment of MyoD to myogenic promoters prior to the onset of differentiation can be 307 accomplished by different mechanisms, including gene-specific mechanisms (24, 40, 59 ). The 308 continued presence of MyoD on myogenic promoters after the onset of differentiation requires the 309 Brg1 ATPase (15, 40). We would therefore predict that the inhibition of calcineurin would affect 310 the interaction of MyoD with myogenic gene regulatory sequences. We assessed MyoD 311 enrichment at the regulatory sequences of tested genes by ChIP. As shown in Fig. 8 
Cn broadly contributes to the activation of the myogenic gene expression program during 320 differentiation 321
The data presented here demonstrate that Cn plays a general role in regulating myogenic gene 322 expression during the myoblast differentiation. Its mechanism of action is via direct promoter 323 binding and dephosphorylation of the Brg1 ATPase of the mammalian SWI/SNF chromatin 324 remodeling enzyme, which regulates the ability of Brg1 and other SWI/SNF enzyme subunits to 325 stably associated with myogenic promoters during differentiation. Failure of this regulatory step 326 prevents the required enzymatic remodeling of promoter chromatin structure and subsequent gene 327 activation during differentiation. 328
The consistent observation of Cn binding to each of the myogenic promoters assayed 329 suggests that Cn is directly required for the activation of each target gene. The alternative 330 hypothesis was that Cn required indirectly via a requirement for activation of myogenin, which is 331 required for activation of myogenic gene products that promote terminal differentiation (60, 61). 332
In prior work examining other cofactors of myogenic gene expression, we determined that the 333 SWI/SNF chromatin remodeling enzyme was required for the expression of both myogenin and 334 subsequent gene expression (57). These new results spatially link Cn and SWI/SNF enzyme 335 binding to myogenic promoters, which is consistent with Cn function being required for SWI/SNF 336 enzyme function. In contrast, the Prmt5 arginine methyltransferase is required for myogenin 337 activation, but ectopic expression of myogenin promoted myogenic gene expression and 338 differentiation even in the absence of Prmt5 (62) The literature on which specific enzyme complex(es) act at muscle-specific promoters is 358 limited. Brg1 has been identified at many myogenic promoters. Interference with Brg1 function 359 through expression of a dominant negative enzyme, injection of specific antibodies, or via 360 knockdown blocks myogenic gene expression and differentiation (15, 16, 24, 40, 65) , but these 361 data do not distinguish between different types of SWI/SNF enzymes. The Brm ATPase binds to 362 the myogenin promoter in isolated mouse myofibers, but not in isolated satellite cells (66), 363 however, knockdown of Brm in cultured myoblasts had limited effect on differentiation-specific 364 gene expression while instead affecting cell cycle withdrawal (65). Those data indicate that A/BAF 365 complex function is a necessary pre-requisite for myoblast differentiation. In mouse heart 366 development, the B/PBAF specific subunits BAF200 and BAF180 are required (67-69), but 367
Baf250A knockout in mouse neural crest leads to embryonic death due to defective cardiac 368 development (70). Despite the intriguing ramifications of thousands of different potential 369 SWI/SNF enzyme compositions, comparison of complexes formed by A/BAF and B/PBAF-370 specific subunits in the same cell type showed that genomic binding sites and transcriptionally 371 responsive genes largely overlapped, leading to the conclusion that the regulation of gene 372 expression by SWI/SNF enzymes is due to the combined effect of multiple SWI/SNF enzymes 373 (71). Muscle development and differentiation may similarly rely on multiple SWI/SNF enzyme 374 assemblies and may not be attributable to one specific enzyme complex. 375
Regulation of SWI/SNF chromatin remodeling enzyme activity, via control of the 376 phosphorylation state of different proteins within the enzyme complex, is an emerging complexity 377 that adds to the alarming complexity posed by the thousands of potential combinatorial assemblies 378 of the enzyme complex from its component subunit proteins (12, 19) . Nevertheless, the evidence 379 for this additional layer of regulation is clear. Amino acids 5' and 3' to the Brg1 bromodomain are 380 phosphorylated by PKCb1 in proliferating myoblasts and dephosphorylated by Cn after the onset 381 of differentiation signaling. Failure to remove the phosphorylation prevents remodeling enzyme 382 function and differentiation, while mutation of these amino acids to prevent phosphorylation 383 permits function even in the presence of a Cn inhibitor (20). Here we demonstrate the generality 384 of the requirement for Cn-mediated facilitation of Brg1 function. The PKCb1/Cn axis is joined by 385 p38 kinase-mediated phosphorylation of the Baf60c subunit that permits assembly of the SWI/SNF 386 enzyme complex on myogenic promoters (24). Most of the SWI/SNF subunits have been 387 characterized as phosphoproteins (72), suggesting that regulation of activity in response to 388 differentiation signaling may be influenced by other kinases and phosphatases as well. 389
The consequences of phosphorylation and dephosphorylation of the PKCb1/Cn-targeted 390 amino acids on Brg1 structure remain to be determined. The fact that Brg1 protein remains present 391 when the relevant amino acids are mutated or when exposed to Cn inhibitor indicates that the 392 phosphorylation state of these amino acids does not significantly contribute to Brg1 protein 393 stability. The failure of other SWI/SNF subunits to remain associated with myogenic gene 394 chromatin suggests that the phosphorylation state may control Brg1 protein conformation, 395 interactions with chromatin, interactions with other SWI/SNF enzyme subunits, and/or interactions 396 with other cofactors that contribute to enzyme complex stability or chromatin binding. Additional 397 characterization will improve our understanding of Brg1 and SWI/SNF chromatin remodeling 398 enzyme function in differentiation and may also inform studies on the role of Brg1 in oncogenesis, 399 where Brg1 can be either mutated or overexpressed without mutation in different types of cancer 400 (73, 74 ChIP assays were performed for Cn or Brg1 binding in primary mouse myoblasts (C57Bl/6), in primary mouse myoblasts deleted for the gene encoding Brg1 (Brg1c/c), or in primary mouse myoblasts deleted for the gene encoding Brg1 that are expressing a wildtype (WT-Brg1), Brg1 containing a non-phosphorylatable amino acid at Cn-targeted sites (SA-Brg1), or Brg1 containing a phosphomimetic amino acid at Cn-targeted sites (SE-Brg1). Samples were collected from proliferating cells in growth medium (GM) or at 24h post-differentiation (DM). Relative enrichment was defined as the ratio of amplification of the PCR product normalized to control IgG and is shown relative to amplification of a non-specific control promoter region. The data are average of 3 independent experiments performed in triplicate +/-SD. * p ≤ 0.05, ** p ≤ 0.01, ***p≤ 0.001 by Student's t-test. . Relative enrichment was defined as the ratio of amplification of the PCR product normalized to control IgG and is shown relative to amplification of a non-specific control promoter region. The data are average of at least 3 independent experiments performed in triplicate +/-SD. * p ≤ 0.05; ** p ≤ 0.01, *** p≤ 0.001 vs. GM or vehicle by Student's t-test.
